E. Bridges

发表

Salivary uric acid as a noninvasive biomarker of metabolic syndrome

Derek G Rodeback, Lance Ridpath, M. Soukup, 2012, Diabetology & Metabolic Syndrome.

Detection of Homocysteine and C-Reactive Protein in the Saliva of Healthy Adults: Comparison with Blood Levels

D. Opriș, E. Bridges, Andrea M. Nazar, 2010, Biomarker insights.

Anti-Hepatitis B Virus Activity and Metabolism of 2′,3′-Dideoxy-2′,3′-Didehydro-β-l(−)-5-Fluorocytidine

Shwu-Huey Liu, E. Bridges, G. Dutschman, 1998, Antimicrobial Agents and Chemotherapy.

Nonclinical Safety Profile of Telbivudine, a Novel Potent Antiviral Agent for Treatment of Hepatitis B

E. Bridges, J. Selden, S. Luo, 2008, Antimicrobial Agents and Chemotherapy.

Toxicological study of the anti-HBV agent β-L-thymidine

B. Tennant, J. Imbach, J. Sommadossi, 2003 .

ANTI-HBV SPECIFIC β-L-2′-DEOXYNUCLEOSIDES

R. Schinazi, B. Tennant, J. Imbach, 2001 .

Favorable interaction of beta-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus.

Y. Cheng, E. Gullen, E. Bridges, 1996, Biochemical pharmacology.

Characterization of a dCTP Transport Activity Reconstituted from Human Mitochondria*

Z. Jiang, E. Bridges, Yung‐chi Cheng, 1999, The Journal of Biological Chemistry.

and Shouqi Luo of Hepatitis B Novel Potent Antiviral Agent for Treatment Nonclinical Safety Profile of Telbivudine , a

E. Bridges, J. Selden, S. Luo, 2008 .

Monoval-LdC: Efficient Prodrug of 2′-Deoxy-β-L-cytidine (L-dC), A Potent and Selective Anti-HBV Agent

D. Bardiot, C. Pierra, D. Standring, 2003, Nucleosides, nucleotides & nucleic acids.

2′-C-Methyl Branched Pyrimidine Ribonucleoside Analogues: Potent Inhibitors of RNA Virus Replication

M. Tausek, S. Bergelson, V. Bichko, 2007, Antiviral chemistry & chemotherapy.

Antiviral l-Nucleosides Specific for Hepatitis B Virus Infection

R. Schinazi, P. Marion, B. Tennant, 2001, Antimicrobial Agents and Chemotherapy.

Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine.

John Mao, R. Storer, J. Sommadossi, 2006, Journal of medicinal chemistry.

Synthesis, Physicochemical and Pharmacokinetic Studies of Potential Prodrugs of β-L-2′-Deoxycytidine, a Selective and Specific Anti-HBV Agent

P. la Colla, J. Sommadossi, C. Pierra, 2004, Antiviral chemistry & chemotherapy.

Pharmacokinetics of β-L-thymidine and β-L-2′-deoxycytidine in woodchucks and monkeys

B. Tennant, J. Imbach, J. Sommadossi, 2003 .

Pharmacology of β-l-Thymidine and β-l-2′-Deoxycytidine in HepG2 Cells and Primary Human Hepatocytes: Relevance to Chemotherapeutic Efficacy against Hepatitis B Virus

J. Rodríguez-Orengo, J. Imbach, J. Sommadossi, 2002, Antimicrobial Agents and Chemotherapy.

Effects of 2',3'-dideoxynucleosides on proliferation and differentiation of human pluripotent progenitors in liquid culture and their effects on mitochondrial DNA synthesis

J. Sommadossi, E. Bridges, A. Faraj, 1994, Antimicrobial Agents and Chemotherapy.

Antiviral beta-L-nucleosides specific for hepatitis B virus infection.

R. Schinazi, M. Myers, B. Tennant, 2001, Antiviral chemistry & chemotherapy.

Pharmacology of beta-L-thymidine and beta-L-2'-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus.

J. Rodríguez-Orengo, J. Imbach, J. Sommadossi, 2002, Antimicrobial Agents and Chemotherapy.

388 Telbivudine preclinical safety studies suggest minimal risk of chronic toxicity, reproductive toxicity or carcinogenicity

E. Bridges, 2006 .

Chapter 21 – Antiviral β-L-nucleosides specific for hepatitis B virus infection

R. Schinazi, M. Myers, B. Tennant, 2003 .

Metabolism of 2′,3′-Dideoxy-2′,3′-Didehydro-β-l(−)-5-Fluorocytidine and Its Activity in Combination with Clinically Approved Anti-Human Immunodeficiency Virus β-d(+) Nucleoside Analogs In Vitro

M. Kukhanova, E. Gullen, Shwu-Huey Liu, 1998, Antimicrobial Agents and Chemotherapy.

Favorable interaction of β-l(−) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus

E. Gullen, E. Bridges, G. Dutschman, 1996 .

Use of novel beta-L(-)-nucleoside analogues for treatment and prevention of chronic hepatitis B virus infection and hepatocellular carcinoma.

Y. Cheng, E. Bridges, 1995, Progress in liver diseases.

NM 283 has potent antiviral activity against genotype 1 chronic hepatitis C virus (HCV-1) infection in the chimpanzee

M. Tausek, R. Chung, R. Lanford, 2003 .

3‘‐Azido‐ 3’‐deoxythymidine inhibits erythroid‐specific transcription factors in human erythroid K562 leukemia cells

J. Sommadossi, P. Jeannesson, C. Trentesaux, 2009, European journal of haematology.

Inhibition of mammalian DNA polymerase-associated 3' to 5' exonuclease activity by 5'-monophosphates of 3'-azido-3'-deoxythymidine and 3'-amino-3'-deoxythymidine.

J. Sommadossi, E. Bridges, A. Faraj, 1993, Biochemical pharmacology.

Comparative effects of 3'-azido-3'-deoxythymidine and its metabolite 3'-amino-3'-deoxythymidine on hemoglobin synthesis in K-562 human leukemia cells.

D. Weidner, J. Sommadossi, E. Bridges, 1992, Molecular pharmacology.

ANTI-HBV SPECIFIC β-L-2′-DEOXYNUCLEOSIDES

R. Schinazi, B. Tennant, J. Imbach, 2001 .

Influence of template primary structure on 3'-azido-3'-deoxythymidine triphosphate incorporation into DNA.

D. Weidner, J. Sommadossi, E. Bridges, 1993, Antiviral Research.